Amicus Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Welcome everybody to the 42nd Annual JP Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. And I'm joined by my squad Malcolm Kuno, Priyanka Grover, and LaRhea Hall.
Our next presenting company is Amicus, and presenting on behalf of the company, we've CEO, Brad Campbell. Brad?
Thanks a lot, Anupam, JPMorgan, for hosting us. It's great to be here. It's always a great way to start the year. Everybody's been reflecting on how nice it is to have sunshine outside, a better macro environment. It's a good time to be a biotech CEO with two commercial products, and we'll talk a lot more about Amicus. Of course, I'll be making forward looking statements. As always, we refer you to our Safe Harbor provisions.
Amicus Therapeutics, we are a company that was founded on the idea that we could make next-generation therapies for people living with rare and orphan diseases. And after almost 20 years
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |